The startup Nolla Health launched a one-year pilot program in Utah on October 5, 2026, using its Nolla Derm app to analyze photos and medical histories of adults with mild-to-moderate acne.

Overview Debates Related claims Topics Sources

Essex Partnership University NHS Foundation Trust spent a net total of £4.3 million on Oxevision installation, software fees, and staff training between 2020 and 2025.

Swedish researchers tested the Dermalyser AI smartphone app across 36 primary care centers from May to December 2022, evaluating 253 suspicious skin lesions in 228 patients.

Mass General Brigham radiation oncologist Dr. Raymond Mak stated that the AI facial tools aim to quantify patient physical reserve and frailty to support personalized treatment decisions.

The FAHR-FaceAge tool estimates a patient's biological age from a photo, while FAHR-FaceSurvival predicts cancer survival outcomes directly from a facial photograph.

Mass General Brigham researchers developed FAHR-Face, an artificial intelligence foundation model that powers two medical prediction tools called FAHR-FaceAge and FAHR-FaceSurvival.

The deployment of the AI triage device reduced routine dermatology follow-up appointments from 27% under standard teledermatology down to 12%.

Use of the AI medical device lowered patient biopsy rates to between 26% and 29%, compared to 43% under standard face-to-face dermatological care.

Researchers deployed the autonomous AI device in December 2024 and July 2025 at two National Health Service hospital sites in the United Kingdom, managing 8,391 patients.

An autonomous artificial intelligence device successfully managed 94% of urgent suspected skin cancer referrals during a 16-month study conducted across two U.K. hospital sites.

Researchers estimated that integrating the AI medical device resulted in a 62% increase in overall clinical capacity for dermatologists.

The AI triage device safely discharged 31% and 25% of benign skin cancer cases without clinician review at the two U.K. hospital sites.

The implementation of the AI device saved approximately 2,850 hours of clinician time, equivalent to over 8,500 face-to-face dermatology consultations.

Colon and rectal surgery expert Dr. Grace Lee stated that the FaceSurvival tool provides a standardized method to quantify clinicians' intuitive visual assessments of patient frailty.

Mass General Brigham researchers filed a patent application for the FaceSurvival artificial intelligence tool.

Penn Medicine researchers designed the Percival artificial intelligence model to advance opportunistic screening, allowing clinicians to discover early traces of unrequested health conditions like cancer or cardiovascular disease on scans ordered for other primary reasons.

Isomorphic Labs established partnerships with major pharmaceutical companies while planning to design internal therapeutic drugs using artificial intelligence.

Isomorphic Labs held funding discussions at a valuation of at least $40 billion, five months after raising $2.1 billion led by Thrive Capital.

On October 15, 2026, U.K. drugmaker AstraZeneca announced a partnership with artificial intelligence startup Insitro to discover new treatments for cardiometabolic diseases

Publicly traded artificial intelligence drug discovery companies have struggled following their initial public offerings amid industry concerns regarding overstated capabilities

Billions of dollars have been invested in young artificial intelligence drug discovery companies, while several large firms have begun integrating AI technology across their operations